References

Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study

10.1136/bmjopen-2013-004251 · 2014 · External reference

Long-term survival after kidney transplantation

10.1056/nejmra2014530 · 2021 · External reference

Trends and specific causes of cardiovascular mortality after kidney transplantation in Finland

10.2215/cjn.0000000000000360 · 2024 · External reference

Infection and malignancy outweigh cardiovascular mortality in kidney transplant recipients: post hoc analysis of the FAVORIT trial

10.1016/j.amjmed.2017.08.038 · 2018 · External reference

Highly sensitized patients are well served by receiving a compatible organ offer based on acceptable mismatches

10.3389/fimmu.2021.687254 · 2021 · External reference

Desensitization in crossmatch-positive kidney transplant candidates

10.1097/tp.0000000000004279 · 2023 · External reference

Imlifidase: first approval

10.1007/s40265-020-01418-5 · 2020 · External reference

Imlifidase therapy: exploring its clinical uses

10.1080/14656566.2022.2150965 · 2023 · External reference

Imlifidase desensitization in HLA-incompatible kidney transplantation: finding the sweet spot

10.1097/tp.0000000000004689 · 2024 · External reference

IgG endopeptidase in highly sensitized patients undergoing transplantation

10.1056/nejmoa1612567 · 2017 · External reference

Is delayed graft function causally associated with long-term outcomes after kidney transplantation? Instrumental variable analysis

10.1097/tp.0b013e3182855544 · 2013 · External reference

Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis

10.1093/ndt/gfn667 · 2009 · External reference

The association between early graft function, donor type and long-term kidney transplant outcomes

10.3389/ti.2025.14197 · 2025 · External reference

Association between duration of delayed graft function, acute rejection, and allograft outcome after deceased donor kidney transplantation

10.1097/tp.0000000000002275 · 2019 · External reference

Prolonged delayed graft function is associated with inferior patient and kidney allograft survivals

10.1371/journal.pone.0144188 · 2015 · External reference

Evaluation of severity of delayed graft function in kidney transplant recipients

10.1093/ndt/gfab304 · 2022 · External reference

The recovery status from delayed graft function can predict long-term outcome after deceased donor kidney transplantation

10.1038/s41598-017-14154-w · 2017 · External reference

Risk factors for delayed graft function in patients with kidney transplantation: a systematic review and meta-analysis

10.1136/bmjopen-2024-087128 · 2025 · External reference

Exploring the causes of the high incidence of delayed graft function after kidney transplantation in Brazil: a multicenter study

10.1111/tri.13865 · 2021 · External reference

Influence of deceased donor hemodynamic factors in transplant recipients renal function

10.5935/0101-2800.20130048 · 2013 · External reference

Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantation

2024 · External reference

Randomized trial of machine perfusion versus cold storage in recipients of deceased donor kidney transplants with high incidence of delayed graft function

10.1097/txd.0000000000000672 · 2017 · External reference

Use of machine perfusion to increase the number of expanded criteria deceased donor kidney transplants: a pharmacoeconomic analysis

10.1097/txd.0000000000001668 · 2024 · External reference

Kidney machine perfusion is associated with improved long-term graft survival mediated by reduced delayed graft function: a mate-kidney analysis

2025 · External reference

Rationale for targeting complement to mitigate renal transplant ischemia-reperfusion injury

2025 · External reference

Complement recognition pathways in renal transplantation

10.1681/asn.2017010079 · 2017 · External reference

Exploring potential complement modulation strategies for ischemia-reperfusion injury in kidney transplantation

10.3390/antiox14010066 · 2025 · External reference

Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation

10.2215/cjn.02200312 · 2012 · External reference

Early activation of the complement system after brain death in clinical kidney donation and transplantation

10.1097/tp.0000000000005520 · 2025 · External reference

The multifaceted role of complement in kidney transplantation

10.1038/s41581-018-0071-x · 2018 · External reference

C1-Inhibitor: structure, functional diversity and therapeutic development

10.2174/0929867328666210804085636 · 2022 · External reference

A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients

10.1111/ajt.14767 · 2018 · External reference

Three-year outcomes of a randomized, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients

10.2215/cjn.04840419 · 2020 · External reference

Structural basis for eculizumab-mediated inhibition of the complement terminal pathway

10.4049/jimmunol.1600280 · 2016 · External reference

Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation

10.1182/blood-2016-08-732800 · 2017 · External reference

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies

10.1111/bjh.16711 · 2020 · External reference

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart

10.1038/s41467-025-62925-1 · 2025 · External reference

Pegcetacoplan: first approval

10.1007/s40265-021-01560-8 · 2021 · External reference

KDIGO clinical practice guideline for the care of kidney transplant recipients

10.1111/j.1600-6143.2009.02834.x · 2009 · External reference

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients

2017 · External reference

A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation

10.1111/ajt.16002 · 2020 · External reference

Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies

10.1097/tp.0000000000002913 · 2020 · External reference

Adverse drug events after kidney transplantation

10.3390/jpm13121706 · 2023 · External reference

Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation

10.1111/ajt.15342 · 2019 · External reference

Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection

2009 · External reference

Non-adherence to immunosuppressive medications in kidney transplant recipients- a systematic scoping review

10.1016/j.trre.2024.100900 · 2025 · External reference

Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro

10.1111/ajt.15533 · 2020 · External reference

Siplizumab, an Anti-CD2 monoclonal antibody, induces a unique set of immune modulatory effects compared to alemtuzumab and rabbit anti-thymocyte globulin in vitro

10.3389/fimmu.2020.592553 · 2020 · External reference

Costimulation blockade in kidney transplant recipients

10.1007/s40265-019-01226-6 · 2020 · External reference

The Inhibition of CD40/CD154 costimulatory signaling in the prevention of renal transplant rejection in nonhuman primates: a systematic review and meta analysis

10.3389/fimmu.2022.861471 · 2022 · External reference

Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint

10.1016/j.pharmthera.2020.107709 · 2021 · External reference

CD40-CD40L blockade: update on novel investigational therapeutics for transplantation

10.1097/tp.0000000000004469 · 2023 · External reference

Inhibition of CD40L with frexalimab in multiple sclerosis

10.1056/nejmoa2309439 · 2024 · External reference

The Role of the CD28 family receptors in T-Cell immunomodulation

10.3390/ijms25021274 · 2024 · External reference

Molecular and cellular functions of CTLA-4

10.1007/978-981-15-3266-5_2 · 2020 · External reference

New developments and therapeutic drug monitoring options in costimulatory blockade in solid organ transplantation: a systematic critical review

10.1097/ftd.0000000000001275 · 2025 · External reference

Interaction of human PD-L1 and B7-1

10.1016/j.molimm.2008.05.014 · 2008 · External reference

B7-h2 is a costimulatory ligand for CD28 in human

10.1016/j.immuni.2011.03.014 · 2011 · External reference

Selective costimulation blockade with antagonist anti-CD28 therapeutics in transplantation

10.1097/tp.0000000000002740 · 2019 · External reference

FR104, an antagonist anti-CD28 monovalent fab’ antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft

10.1111/ajt.12964 · 2015 · External reference

First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28

10.4049/jimmunol.1601538 · 2016 · External reference

Clinical consequences of circulating CD28-negative T cells for solid organ transplantation

10.1111/tri.12658 · 2016 · External reference

mTOR inhibitor therapy diminishes circulating CD8+ CD28- effector memory T Cells and improves allograft inflammation in belatacept-refractory renal allograft rejection

10.1097/tp.0000000000002917 · 2020 · External reference

Acute rejection after kidney transplant-an endpoint not predictive of treatment effect on graft survival

10.1097/tp.0000000000004696 · 2024 · External reference

Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study

10.1136/bmj.l4923 · 2019 · External reference

Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival

10.1016/j.ajt.2024.04.004 · 2024 · External reference

Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients

10.1111/j.1600-6143.2010.03338.x · 2011 · External reference

Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients

10.1111/ajt.16386 · 2021 · External reference

Combined anti-CD154/CTLA4Ig costimulation blockade-based therapy induces donor-specific tolerance to vascularized osteomyocutaneous allografts

10.1111/ajt.13694 · 2016 · External reference

Tolerance in the age of immunotherapy

10.1056/nejmra1911109 · 2020 · External reference

Strategies for long-term preservation of kidney graft function

10.1016/s0140-6736(17)31283-7 · 2017 · External reference

Antibody-mediated rejection of solid-organ allografts

10.1056/nejmra1802677 · 2018 · External reference

Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: A systematic review

10.1111/ctr.14320 · 2021 · External reference

New insights regarding chronic antibody-mediated rejection and its progression to transplant glomerulopathy

10.1097/mnh.0000000000000070 · 2014 · External reference

Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials

10.1080/14728214.2022.2091131 · 2022 · External reference

Translating B cell immunology to the treatment of antibody-mediated allograft rejection

10.1038/s41581-023-00791-0 · 2024 · External reference

CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity

10.3389/fimmu.2020.597959 · 2020 · External reference

The CD38 glycohydrolase and the NAD sink: implications for pathological conditions

10.1152/ajpcell.00451.2021 · 2022 · External reference

CD38 antibodies in multiple myeloma: back to the future

10.1182/blood-2017-06-740944 · 2018 · External reference

A randomized phase 2 trial of felzartamab in antibody-mediated rejection

10.1056/nejmoa2400763 · 2024 · External reference

Complement in antibody-mediated rejection of the kidney graft: from pathophysiology to clinical practice

10.3390/jcm14082810 · 2025 · External reference

Knockdown of target genes by siRNA in vitro

10.1007/978-1-0716-1217-0_10 · 2021 · External reference

Microvascular inflammation in kidney allografts: new directions for patient management

10.1016/j.ajt.2025.03.031 · 2025 · External reference

A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejection

10.1016/j.kint.2022.09.030 · 2023 · External reference

Continuous indices to assess the phenotypic spectrum of kidney transplant rejection

10.1038/s41467-025-65153-9 · 2025 · External reference

FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study

10.1097/01.tp.0000281385.26500.3b · 2007 · External reference

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year

10.1111/j.1600-6143.2012.04127.x · 2012 · External reference

Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results

10.1111/ajt.12251 · 2013 · External reference

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database

10.3389/fphar.2024.1440907 · 2024 · External reference

Costimulatory blockade and infectious risk in solid organ transplantation

10.1016/j.ajt.2025.12.284 · 2026 · External reference